

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David B. Volkin et al.

Serial No. to be assigned

Filed:

For: POLYNUCLEOTIDE VACCINE FORMULATIONS

Art Unit: 1632Examiner: Anne Marie Sabina
WehbeCommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT January 26, 2004
EXPRESS MAIL NO. EV 323153073US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Lou Schegier
DATE 1-26-04

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By _____ Date _____

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:


RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: J. Mark Hand

Attorney _____ For Applicant(s)

Reg. No. 36,545

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3905

Date: JANUARY 26, 2004



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number		
			Filing Date		
			First Named Inventor	D. Volkin	
			Group Art Unit	1632	
			Examiner Name	Anne Marie Sabrina Wehbe	
Sheet	2	of	3	Attorney Docket Number	19907YIACB

OTHER NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	A	Haynes et al. 'Update on the Issues of HIV Vaccine Development', Ann Med. Vol 28, pp 39-41, 1996
	B	Chiang et al. Research and Development of Adjuvants for Cell Culture Derived Japanese Encephalitis Vaccine', J. of Microbiology Immunology and Infection, Vol 31, No. 1, pp 58-63, 1998
	C	Hem et al. 'Accessibility of Antigen in Vaccines Produced by in Situ Alum Precipitation', Vaccine Research, Vol 5, No. pp 187-191, 1996
	D	Brubaker et al. Th1-Associated Immune Responses...Replication Defective Herpes Simplex Virus', J. of Immunology, Vol. 157, No. 4 pp 1598-1604, 1996
	E	Rinella et al. Elutability of Proteins from Aluminum-Containing Vaccine Adjuvants by Treatment with Surfactants', J. of Colloid and Interface Science, Vol. 197, No. 1 pp 48-56, 1998
	F	York et al. Immunomodulatory effects of HSV2...for immunotherapy of recurrent HSV infection', Vaccine, Vol. 13, No. 17, pp 1706-1712, 1995
	G	McClements et al. Immunization with DNA vaccines...herpes simplex virus-2 disease' Proc. Natl. Acad. Sci., Vol. 93, pp 11414-11420, 1998
	H	Manickan et al. Genetic Immunization Against Herpes Simplex Virus', J. of Immunology, Vol 155, NO. 1 pp. 259-265, 1995
	I	Berman et al. Protection from Genital Herpes Simplex Virus Type 1...Glycoprotein D', Science, Vol 227, pp 1490-1492 1985
	J	York et al. Immunomodulatory effects of HSV... HSV infection', Vaccine, Vol 13, pp 1706-1712, 1998
	K	Ross et al. 'Gene Therapy in the United States: A five-year Status Report', Human Gene Therapy, Vol 7, pp 1781-1790, 1996
	L	Dropulic et al. 'Gene Therapy for Human Immunodeficiency Virus Infection: Genetic Antiviral Strategies and Targets for Intervention', Human Gene Therapy, Vol. 5 pp 927-939, 1994
	M	Essex et al. 'Gene Therapy Against Retroviral Diseases', Leukemia, Vol. 9 Suppl. 1, S71-S74, 1995
	N	Durrani et al. Intranasal immunization with a plant virus...than oral immunization', J. of Immunological Methods, Vol. 220, pp 93-103, 1998
	O	Miller et al. Targeted vectors for gene therapy', FASEB J. Vol. 9, pp 109-199, 1995

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	
				Filing Date	
				First Named Inventor	D. Volkin
				Group Art Unit	1632
				Examiner Name	Anne Marie Sabrina Wehbe
Sheet	3	of	3	Attorney Docket Number	19907YIACB

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	P	Crystal et al. 'Transfer of Genes to Humans: Early Lessons and Obstacles to Cussess', Science Vol. 270, pp 404-410, 1995
	Q	Deonarain, 'Ligand-targeted receptor-mediated vectors for gene delivery', exp. Opin. Ther. Patents, Vol. 8 pp 53-69, 1998
	R	Verma et al. 'Gene Therapy-promises, problems and prospects', Nature, Vol. 389, pp 239-242, 1997
	S	Orkin et al., 'Reports and Recommendations fo the Panel...on Gene Therapy', NIH Report and Recommendations 1995
	T	Frynan et al. 'DNA Vaccines: protective imminizations by parenteral, mucosal and gene gun inoculations', Proc. Nat. Acad. of Sci., Vol. 90, pp11478-11482, 1993
	U	Ulmer et al. 'Toward the development of DNA vaccines', Current Opinion in Biotechnology, Vol. 7, No. 6, pp 653-568, 1996
	V	Benevisty et al. 'Direct Introduction of genes into rates and expression of the genes', Proceedings of the National Academy of Sciences, USA, Vol. 83, No. 24, pp 9551-9555, 1986
	W	Gupta et al. 'Adjuvants for human vaccines - current status, problems and future prospects', Vaccine, Vol. 13, No. 14, p 1269, 1995
	X	Yasutomi et al., 'A Vaccine-Elicited, Single Viral Epitope-Specific Tytotoxic T...Immunodeficiency Virus Challenge', Journal of Virology, pp 2279-2284, 1995
	Y	Ertl et al. 'Genetic Immunizaiton', Viral Immunology, Vol 9, pp 1-9, 1996
	Z	Monteil et al. 'Genetic immunization of seronegative one-day-old piglets...from immune dams', Genetic Immunization, Vol. 27, pp 443-452, 1996
	AA	Golding et al.. 'The Potential for Recruiting Immune Responses Toward Type 1 or Type 2 Cell Help', American Society of Tropical medicine and Hygiene, pp 33-40, 1994
	AB	Xiang et al. 'Vaccination with a Plasmid Vector Carrying the Rabies Virus Glycoprotein Gene Induces Protective Immunity against Rabies Virus', Virology, Vol. 199, pp 132-140, 1994
	AC	Marshall, 'Gene Therapy's Growing Pains', Science, Vol. 269, pp 1050-1055, 1995
	AD	Restifo et al. 'Molecular Mechanisms Used by Tumors to Escape Immune Recognition:... Complex Class I', Journal of Immunology, Vol. 14, pp 182-190, 1993

Examiner Signature		Date Considered	
--------------------	--	-----------------	--